KFFs analysis of newly released Medicare Part D spending data from CMS shows that total gross Medicare spending on the three newest versions of these diabetes medications that have also been recently approved for weight loss Ozempic, Rybelsus, and Mounjaro has skyrocketed in recent years, rising from $57 million in 2018 to $5.7 billion in 2022 (Figure 1)
The interaction between these medications and altered GLP-1 levels could affect blood sugar management in ways that need monitoring
The medication's mechanism of slowing gastric emptying makes dietary modifications particularly important for tolerability
Others, like a food sensitivity or an undiagnosed condition, may be harder to identify
But its their weight loss effects that have caused a surge in interest
Because physicians own this multispecialty facility, we maintain the very highest clinical standards and adhere to a strict policy of transparencyso our patients never need to worry about hidden costs
:max_bytes(150000):strip_icc()/VWH-AmeliaManley-OzempicvsWegovyvsMounjaro-dc80b8c8de6243ec9b984cd4b5db5db4.jpg)
